Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases
Abstract
:1. Introduction
2. Case Reports
2.1. Subject 1
2.2. Subject 2
3. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- D’Agati, E.; Curatolo, P.; Mazzone, L. Comorbidity between ADHD and anxiety disorders across the lifespan. Int. J. Psychiatry Clin. Pr. 2019, 23, 238–244. [Google Scholar] [CrossRef] [PubMed]
- Eyre, O.; Langley, K.; Stringaris, A.; Leibenluft, E.; Collishaw, S.; Thapar, A. Irritability in ADHD: Associations with depression liability. J. Affect. Disord. 2017, 215, 281–287. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lambez, B.; Harwood-Gross, A.; Golumbic, E.Z.; Rassovsky, Y. Non-pharmacological interventions for cognitive difficulties in ADHD: A systematic review and meta-analysis. J. Psychiatr. Res. 2020, 120, 40–55. [Google Scholar] [CrossRef] [PubMed]
- Guy, W. ECDEU Assessment Manual for Psychopharmacology; Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration: Rockville, MD, USA, 1976. [Google Scholar]
- Conners, C.K.; Sitarenios, G.; Parker, J.D.A.; Epstein, J.N. The Revised Conners’ Parent Rating Scale (CPRS-R): Factor Structure, Reliability, and Criterion Validity. J. Abnorm. Child Psychol. 1998, 26, 257–268. [Google Scholar] [CrossRef] [PubMed]
- Bang-Andersen, B.; Ruhland, T.; Jørgensen, M.; Smith, G.; Frederiksen, K.; Jensen, K.G.; Zhong, H.; Nielsen, S.M.; Hogg, S.; Mørk, A.; et al. Discovery of 1-[2-(2, 4-Dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder. J. Med. Chem. 2011, 54, 3206–3221. [Google Scholar] [CrossRef] [PubMed]
- Mørk, A.; Pehrson, A.; Brennum, L.T.; Nielsen, S.M.; Zhong, H.; Lassen, A.B.; Miller, S.; Westrich, L.; Boyle, N.J.; Sánchez, C.; et al. Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder. J. Pharmacol. Exp. Ther. 2011, 340, 666–675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Safadi, J.M.; Quinton, A.M.G.; Lennox, B.R.; Burnet, P.W.J.; Minichino, A. Gut dysbiosis in severe mental illness and chronic fatigue: A novel trans-diagnostic construct? A systematic review and meta-analysis. Mol. Psychiatry 2021, 1–13. [Google Scholar] [CrossRef]
- Guessoum, S.B.; Le Strat, Y.; Dubertret, C.; Mallet, J. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2020, 99, 109862. [Google Scholar] [CrossRef] [PubMed]
- Biederman, J.; Lindsten, A.; Sluth, L.B.; Petersen, M.L.; Ettrup, A.; Eriksen, H.-L.F.; Fava, M. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J. Psychopharmacol. 2019, 33, 511–521. [Google Scholar] [CrossRef] [PubMed]
- Findling, R.L.; Robb, A.S.; DelBello, M.P.; Huss, M.; McNamara, N.K.; Sarkis, E.H.; Scheffer, R.E.; Poulsen, L.H.; Chen, G.; Lemming, O.M.; et al. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. J. Child Adolesc. Psychopharmacol. 2018, 28, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Naguy, A.; Alamiri, B. Successful Add-on Vortioxetine for an Adolescent With Attention-Deficit/Hyperactivity Disorder. J. Clin. Psychopharmacol. 2018, 38, 407–409. [Google Scholar] [CrossRef] [PubMed]
- Lamb, Y.N. Viloxazine: Pediatric First Approval. Pediatr. Drugs 2021, 23, 403–409. [Google Scholar] [CrossRef] [PubMed]
- Epstein, J.N.; Loren, R.E.A. Changes in the definition of ADHD in DSM-5: Subtle but important. Neuropsychiatry 2013, 3, 455–458. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cases | Time Point | CGI-S | CGI-I | CGI-E Treatment Efficacy | CGI-E Side Effects |
---|---|---|---|---|---|
Case 1 | T0 | 5 | - | - | - |
T1 | 3 | 2 | Marked | None | |
T2 * | 4 | 5 | Moderate | None | |
T3 | 3 | 3 | Moderate | None | |
Case 2 | T0 | 4 | - | - | - |
T1 | 3 | 3 | Moderate | Do not significantly interfere with patient’s functioning | |
T2 | 2 | 2 | Marked | None | |
T3 | 2 | 2 | Marked | None |
Case | Time Point | Form Type | Conners’ Scale T Score | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case 1 | Family Problems | Emotional Problems | Conduct Problems | Cognitive Problems- Inattention | Anger Control Problems | Hyperactivity | ADHD Index | DSM-IV Inattentive | DSM-IV Hyperactivity/Impulsivity | DSM-IV Total | ||||||
T0 | Self (CASS:L) | 42 | 66 | 53 | 51 | 66 | 74 | 45 | 54 | 60 | 58 | |||||
T1 | Self (CASS:L) | 35 | 43 | 42 | 38 | 53 | 51 | 40 | 46 | 50 | 48 | |||||
T2 * | Self (CASS:L) | 35 | 57 | 42 | 39 | 61 | 70 | 43 | 43 | 52 | 47 | |||||
T3 | Self (CASS:L) | 37 | 66 | 49 | 46 | 66 | 58 | 56 | 50 | 56 | 53 | |||||
Oppositional | Cognitive Problem-Inattention | Hyperactivity | Anxious-Shy | Perfectionism | Social Problems | Psychosomatic | ADHD Index | Restless/Impulsivity | Emotional Lability | Global Index | DSM-IV Inattentive | DSM-IV Hyperactivity | DSM-IV Total | |||
T0 | Parent (CPRS:R) | 62 | 60 | 64 | 94 | 88 | 88 | 63 | 60 | 61 | 53 | 60 | 58 | 67 | 63 | |
T1 | Parent (CPRS:R) | 54 | 52 | 56 | 60 | 62 | 58 | 47 | 51 | 53 | 59 | 55 | 48 | 57 | 53 | |
T2 * | Parent (CPRS:R) | 56 | 55 | 60 | 79 | 69 | 95 | 70 | 55 | 53 | 71 | 58 | 51 | 61 | 57 | |
T3 | Parent (CPRS:R) | 50 | 55 | 58 | 73 | 69 | 88 | 60 | 54 | 53 | 65 | 56 | 50 | 61 | 56 | |
Case 2 | Family Problems | Emotional Problems | Conduct Problems | Cognitive Problems-Inattention | Anger Control Problems | Hyperactivity | ADHD Index | DSM-IV Inattentive | DSM-IV Hyperactivity/Impulsivity | DSM-IV Total | ||||||
T0 | Self (CASS:L) | 42 | 57 | 44 | 64 | 59 | 60 | 60 | 66 | 63 | 67 | |||||
T1 | Self (CASS:L) | 46 | 64 | 44 | 58 | 53 | 67 | 63 | 60 | 62 | 62 | |||||
T2 | Self (CASS:L) | 41 | 47 | 46 | 56 | 44 | 41 | 48 | 51 | 46 | 48 | |||||
T3 | Self (CASS:L) | 41 | 47 | 46 | 56 | 44 | 41 | 49 | 51 | 46 | 48 | |||||
Oppositional | Cognitive Problem-Inattention | Hyperactivity | Anxious-Shy | Perfectionism | Social Problems | Psychosomatic | ADHD Index | Restless/Impulsivity | Emotional Lability | Global Index | DSM-IV Inattentive | DSM-IV Hyperactivity | DSM-IV Total | |||
T0 | Parent (CPRS:R) | 60 | 65 | 60 | 61 | 63 | 90 | 68 | 64 | 64 | 59 | 64 | 59 | 78 | 68 | |
T1 | Parent (CPRS:R) | 52 | 64 | 56 | 55 | 48 | 74 | 48 | 59 | 57 | 59 | 59 | 62 | 62 | 64 | |
T2 | Parent (CPRS:R) | 52 | 64 | 52 | 55 | 48 | 74 | 48 | 57 | 49 | 59 | 59 | 62 | 62 | 64 | |
T3 | Parent (CPRS:R) | 54 | 54 | 48 | 55 | 43 | 74 | 58 | 46 | 45 | 43 | 44 | 47 | 53 | 49 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bortoletto, R.; Puttini, E.; Zoccante, L.; Colizzi, M. Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases. Reports 2021, 4, 30. https://doi.org/10.3390/reports4040030
Bortoletto R, Puttini E, Zoccante L, Colizzi M. Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases. Reports. 2021; 4(4):30. https://doi.org/10.3390/reports4040030
Chicago/Turabian StyleBortoletto, Riccardo, Elena Puttini, Leonardo Zoccante, and Marco Colizzi. 2021. "Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases" Reports 4, no. 4: 30. https://doi.org/10.3390/reports4040030
APA StyleBortoletto, R., Puttini, E., Zoccante, L., & Colizzi, M. (2021). Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases. Reports, 4(4), 30. https://doi.org/10.3390/reports4040030